DeepMed Research

Eisai Korea Inc.

🇰🇷South Korea

Country: 🇰🇷South Korea

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Study of Filgotinib 200 mg in Korean Participants With Moderately to Severely Active Ulcerative Colitis Under Routine Clinical Practice

Phase 4

Not yet recruiting

Conditions: Ulcerative Colitis

Interventions: Drug: Filgotinib Maleate

First Posted Date: 2025-05-09

Last Posted Date: 2025-05-09

Lead Sponsor: Eisai Korea Inc.

Target Recruit Count: 94

Registration Number: NCT06964113

Locations: 🇰🇷
Eisai Site #13, Busan, Korea, Republic of
🇰🇷
Eisai Site #8, Busan, Korea, Republic of
🇰🇷
Eisai Site #7, Chungnam, Korea, Republic of

and more 10 locations

A Postmarketing Study of Lecanemab in South Korean Participants With Alzheimer's Disease

Not yet recruiting

Conditions: Alzheimer's Disease

First Posted Date: 2025-02-06

Last Posted Date: 2025-02-06

Lead Sponsor: Eisai Korea Inc.

Target Recruit Count: 3000

Registration Number: NCT06810960

A Study of Filgotinib in Korean Participants With Rheumatoid Arthritis

Phase 4

Recruiting

Conditions: Rheumatoid Arthritis

Interventions: Drug: Filgotinib Maleate

First Posted Date: 2024-10-03

Last Posted Date: 2025-01-10

Lead Sponsor: Eisai Korea Inc.

Target Recruit Count: 150

Registration Number: NCT06625242

Locations: 🇰🇷
Eisai site #11, Anyang-si, Korea, Republic of
🇰🇷
Eisai site #01, Busan, Korea, Republic of
🇰🇷
Eisai site #09, Daegu, Korea, Republic of

and more 12 locations

A Study of Jyseleca Tablet (Filgotinib Maleate) in Korean Participants

Recruiting

Conditions: Arthritis, Rheumatoid
Colitis, Ulcerative

Interventions: Other: Non-interventional

First Posted Date: 2024-02-07

Last Posted Date: 2025-05-13

Lead Sponsor: Eisai Korea Inc.

Target Recruit Count: 2040

Registration Number: NCT06246123

Locations: 🇰🇷
Site #28, Ansan, Korea, Republic of
🇰🇷
Site #36, Daegu, Korea, Republic of
🇰🇷
Site #35, Gyeonggi, Korea, Republic of

and more 39 locations

A Study to Evaluate the Efficacy and Safety of Perampanel Monotherapy in Untreated Participants With Focal Onset Seizures With or Without Focal to Bilateral Tonic-clonic Seizures

Phase 4

Completed

Conditions: Epilepsy

Interventions: Drug: Perampanel

First Posted Date: 2022-09-09

Last Posted Date: 2025-03-07

Lead Sponsor: Eisai Korea Inc.

Target Recruit Count: 125

Registration Number: NCT05533814

Locations: 🇰🇷
Eisai Site #3, Daejeon, Korea, Republic of
🇰🇷
Eisai Site #10, Jeonju, Korea, Republic of
🇰🇷
Eisai Site #5, Seoul, Korea, Republic of

and more 7 locations

A Study of Lenvatinib in Combination With Pembrolizumab in Korean Patients

Completed

Conditions: Carcinoma
Endometrial Neoplasms
Endometrium
Renal Cell Carcinoma

Interventions: Other: Non-interventional

First Posted Date: 2022-05-16

Last Posted Date: 2024-03-25

Lead Sponsor: Eisai Korea Inc.

Target Recruit Count: 135

Registration Number: NCT05375136

Locations: 🇰🇷
Eisai Site #14, Seoul, Korea, Republic of
🇰🇷
Eisai Site #04, Bundang, Korea, Republic of
🇰🇷
Eisai Site #02, Busan, Korea, Republic of

and more 16 locations

A Study for Tecfidera (Dimethyl Fumarate) Capsules in Korean Participants With Relapsing-Remitting Multiple Sclerosis

Completed

Conditions: Multiple Sclerosis, Relapsing-remitting

Interventions: Other: No Intervention

First Posted Date: 2022-05-09

Last Posted Date: 2022-05-09

Lead Sponsor: Eisai Korea Inc.

Target Recruit Count: 172

Registration Number: NCT05366036

Locations: 🇰🇷
Site #12, Seoul, Korea, Republic of
🇰🇷
Site #03, Kwangju, Korea, Republic of
🇰🇷
Site #01, Daegu, Korea, Republic of

and more 17 locations

A Study to Evaluate the Efficacy and Safety of Safinamide Mesilate as Add-on Therapy to Levodopa in Parkinson's Disease Participants With Motor Fluctuation in South Korea

Phase 4

Completed

Conditions: Parkinson Disease

Interventions: Drug: Safinamide Mesilate

First Posted Date: 2022-04-05

Last Posted Date: 2023-10-18

Lead Sponsor: Eisai Korea Inc.

Target Recruit Count: 201

Registration Number: NCT05312632

Locations: 🇰🇷
Eisai Site #11, Busan, Korea, Republic of
🇰🇷
Eisai Site #3, Busan, Korea, Republic of
🇰🇷
Eisai Site #16, Daegu, Korea, Republic of

and more 17 locations

A Post Marketing Surveillance Study of Equfina Tablet 50 Milligram (mg)

Recruiting

Conditions: Parkinson Disease

Interventions: Drug: Equfina 50 mg

First Posted Date: 2022-02-04

Last Posted Date: 2025-02-14

Lead Sponsor: Eisai Korea Inc.

Target Recruit Count: 600

Registration Number: NCT05225324

Locations: 🇰🇷
Site #03, Cheongju, Chungcheongbuk-do, Korea, Republic of
🇰🇷
Site #11, Ilsan, Gyeonggi-do, Korea, Republic of
🇰🇷
Site #23, Wonju-si, Gangwon-do, Korea, Republic of

and more 24 locations

A Study of Lenvima (Lenvatinib) in Korean Unresectable Hepatocellular Carcinoma (uHCC) Participants

Completed

Conditions: Carcinoma, Hepatocellular
Liver Neoplasms

Interventions: Other: Non-interventional

First Posted Date: 2022-02-04

Last Posted Date: 2023-01-09

Lead Sponsor: Eisai Korea Inc.

Target Recruit Count: 658

Registration Number: NCT05225207

Locations: 🇰🇷
Site #03, Seongnam, Gyeonggi-do, Korea, Republic of
🇰🇷
Site #32, Cheonan, Chungcheongnam-do, Korea, Republic of
🇰🇷
Site #38, Bucheon, Gyeonggi-do, Korea, Republic of

and more 39 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy